Ph: (443) 281-9157

Fax: (410) 582-8728

801 Landmark Dr.
Glen Burnie, MD 21061
Contact Us

Mon-Fri: 8:30AM-6:30PM

Sat: 9:00AM-2:00PM
regen-cov logo

The next step in the fight against COVID-19 is here.

Soleil Pharmacy is providing Monoclonal Antibody Therapy for both treatment AND prophylaxis post-exposure. According to the U.S. Food & Drug Administration (FDA), monoclonal antibody treatments have proven to reduce viral levels and improve symptoms in non-hospitalized COVID patients.

Monoclonal antibodies developed to treat COVID-19 target the spike protein, which corona-virus (SARS-CoV-2) uses to enter the host cells. By binding to the spike protein, a monoclonal antibody can help prevent the virus from infecting human cells.

Monoclonal antibody therapy is a combination of casirivimab and imdevimab (more widely known as Regeneron). mAbs treatment can reduce COVID-19 symptoms, hospitalization or emergency room visits when administered as soon as possible after exposure or within 10 days of symptom onset.

At this time, Soleil Pharmacy is administering Casirivimab and Imdevimab (REGEN-COV) only as In-home treatment because of our space constraints and staff/patients safety at our pharmacy.

Download Fact Sheet for Patients for Regen-Cov

Descargar La Ficha Técnica para Patientes para REGEN-COV

If you are a Healthcare Provider

If you think your patient is a candidate for a monoclonal antibody treatment, fill out the Doctor Referral Form. Here are the options: 

1. Fill out the Doctor Referral Form online.
2. Or print and fax it to to (410) 582-8728 or (443) 281-9157
3. or Fill request on CRISP https://www.crisphealth.org/guidance/providers/

Please share Patient Consent Form and Fact Sheet for Patients for Regen-Cov with your patient.

Please note: There is always the possibility that a patient’s clinical condition may change during the time between referral and injection appointment, to the point where mAb therapy may no longer be indicated for the patient. If a patient has clinically declined by the time of scheduled appointment, we will refer them to a higher level of care, if needed, without administering mAb.

If you are a patient

1. Interested patients should click here to complete a Monoclonal Antibody Interest Form.

2. Our pharmacist will review your form

3. We will contact you to schedule your appointment.

4. mAbs Treatment: You’ll receive a home treatment visit. Receiving mAbs injections take about 3 minutes. There is a 1 hour observation period following the treatment.

Please note: There is always the possibility that a patient’s clinical condition may change during the time between referral and injection appointment, to the point where mAb therapy may no longer be indicated for the patient. If a patient has clinically declined by the time of scheduled appointment, we will refer them to a higher level of care, if needed, without administering mAb.

Who is Eligible for Monoclonal Antibody Treatment?

To be eligible, individuals must meet all of the following criteria:

1) Treatment of Mild-to-moderate COVID-19 with positive results of direct SARS-CoV-2

  • be 12 years or older;
  • weigh at least 88 lbs;
  • be at high risk for progressing to severe COVID-19 (see high risk list below);
  • have tested positive for COVID-19 or been exposed to a positive case;
  • be within 10 days of symptom onset (ideally as soon as possible after diagnosis, even if symptoms are not too bad); AND
  • not be receiving oxygen therapy.

High risk includes any of the following:

  • 65 years or older;
  • Chronic kidney disease;
  • Heart or lung disease;
  • BMI of 25 or greater;
  • Pregnancy;
  • Diabetes;
  • Sickle cell disease;
  • Neurodevelopmental disorders (for example, cerebral palsy);
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID 19); OR
  • Other medical conditions or factors (for example, race or ethnicity) that may also place individual patients at high risk for progression to severe COVID-19.

2) Post-exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:

not fully vaccinated OR who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (e.g. individuals with
immunocompromising conditions including those taking immunosuppressive medications) AND

– have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC) OR

– who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting.

 

Who should NOT receive Monoclonal Antibody Treatment?

Mabs may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow of oxygen or mechanical ventilation. Under the terms of the EUA mAbs are not authorized for use in patients who meet any of the following:

  • Are hospitalized due to COVID-19
  • Require oxygen therapy due to COVID-19
  • Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 realted comorbidity.

What is the cost of treatment?

There is no cost to patients as medications are made available to our pharmacy at no cost. Soleil Pharmacy can bill the patient’s insurance carrier for the administration/visit fee to the patient’s insurance but Soleil Pharmacy can not bill patients.

For uninsured patients, the federal HRSA COVID-19 Coverage Assistance Fund was developed to reimbursed providers for COVID-19 treatments including monoclonal antibody therapy. See this link for more information: https://www.hrsa.gov/coviduninsuredclaim

If you have questions about whether mAb treatment is right for you, contact your physician or give us a call at (443) 281-9157.